drugset / Trial / NCT02551432
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Timeline
- Start
- 2015-09
- Primary completion
- 2017-12
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |